Cargando…
Non-Communicable Disease Clinical Practice Guidelines in Brazil: A Systematic Assessment of Methodological Quality and Transparency
BACKGROUND: Annually, non-communicable diseases (NCDs) kill 38 million people worldwide, with low and middle-income countries accounting for three-quarters of these deaths. High-quality clinical practice guidelines (CPGs) are fundamental to improving NCD management. The present study evaluated the m...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5112889/ https://www.ncbi.nlm.nih.gov/pubmed/27846245 http://dx.doi.org/10.1371/journal.pone.0166367 |
_version_ | 1782468096926154752 |
---|---|
author | Molino, Caroline de Godoi Rezende Costa Romano-Lieber, Nicolina Silvana Ribeiro, Eliane de Melo, Daniela Oliveira |
author_facet | Molino, Caroline de Godoi Rezende Costa Romano-Lieber, Nicolina Silvana Ribeiro, Eliane de Melo, Daniela Oliveira |
author_sort | Molino, Caroline de Godoi Rezende Costa |
collection | PubMed |
description | BACKGROUND: Annually, non-communicable diseases (NCDs) kill 38 million people worldwide, with low and middle-income countries accounting for three-quarters of these deaths. High-quality clinical practice guidelines (CPGs) are fundamental to improving NCD management. The present study evaluated the methodological rigor and transparency of Brazilian CPGs that recommend pharmacological treatment for the most prevalent NCDs. METHODS: We conducted a systematic search for CPGs of the following NCDs: asthma, atrial fibrillation, benign prostatic hyperplasia, chronic obstructive pulmonary disease, congestive heart failure, coronary artery disease and/or stable angina, dementia, depression, diabetes, gastroesophageal reflux disease, hypercholesterolemia, hypertension, osteoarthritis, and osteoporosis. CPGs comprising pharmacological treatment recommendations were included. No language or year restrictions were applied. CPGs were excluded if they were merely for local use and referred to NCDs not listed above. CPG quality was independently assessed by two reviewers using the Appraisal of Guidelines Research and Evaluation instrument, version II (AGREE II). MAIN FINDINGS: “Scope and purpose” and “clarity and presentation” domains received the highest scores. Sixteen of 26 CPGs were classified as low quality, and none were classified as high overall quality. No CPG was recommended without modification (77% were not recommended at all). After 2009, 2 domain scores (“rigor of development” and “clarity and presentation”) increased (61% and 73%, respectively). However, “rigor of development” was still rated < 30%. CONCLUSION: Brazilian healthcare professionals should be concerned with CPG quality for the treatment of selected NCDs. Features that undermined AGREE II scores included the lack of a multidisciplinary team for the development group, no consideration of patients’ preferences, insufficient information regarding literature searches, lack of selection criteria, formulating recommendations, authors’ conflict of interest disclosures, and funding body influence. |
format | Online Article Text |
id | pubmed-5112889 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-51128892016-12-08 Non-Communicable Disease Clinical Practice Guidelines in Brazil: A Systematic Assessment of Methodological Quality and Transparency Molino, Caroline de Godoi Rezende Costa Romano-Lieber, Nicolina Silvana Ribeiro, Eliane de Melo, Daniela Oliveira PLoS One Research Article BACKGROUND: Annually, non-communicable diseases (NCDs) kill 38 million people worldwide, with low and middle-income countries accounting for three-quarters of these deaths. High-quality clinical practice guidelines (CPGs) are fundamental to improving NCD management. The present study evaluated the methodological rigor and transparency of Brazilian CPGs that recommend pharmacological treatment for the most prevalent NCDs. METHODS: We conducted a systematic search for CPGs of the following NCDs: asthma, atrial fibrillation, benign prostatic hyperplasia, chronic obstructive pulmonary disease, congestive heart failure, coronary artery disease and/or stable angina, dementia, depression, diabetes, gastroesophageal reflux disease, hypercholesterolemia, hypertension, osteoarthritis, and osteoporosis. CPGs comprising pharmacological treatment recommendations were included. No language or year restrictions were applied. CPGs were excluded if they were merely for local use and referred to NCDs not listed above. CPG quality was independently assessed by two reviewers using the Appraisal of Guidelines Research and Evaluation instrument, version II (AGREE II). MAIN FINDINGS: “Scope and purpose” and “clarity and presentation” domains received the highest scores. Sixteen of 26 CPGs were classified as low quality, and none were classified as high overall quality. No CPG was recommended without modification (77% were not recommended at all). After 2009, 2 domain scores (“rigor of development” and “clarity and presentation”) increased (61% and 73%, respectively). However, “rigor of development” was still rated < 30%. CONCLUSION: Brazilian healthcare professionals should be concerned with CPG quality for the treatment of selected NCDs. Features that undermined AGREE II scores included the lack of a multidisciplinary team for the development group, no consideration of patients’ preferences, insufficient information regarding literature searches, lack of selection criteria, formulating recommendations, authors’ conflict of interest disclosures, and funding body influence. Public Library of Science 2016-11-15 /pmc/articles/PMC5112889/ /pubmed/27846245 http://dx.doi.org/10.1371/journal.pone.0166367 Text en © 2016 Molino et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Molino, Caroline de Godoi Rezende Costa Romano-Lieber, Nicolina Silvana Ribeiro, Eliane de Melo, Daniela Oliveira Non-Communicable Disease Clinical Practice Guidelines in Brazil: A Systematic Assessment of Methodological Quality and Transparency |
title | Non-Communicable Disease Clinical Practice Guidelines in Brazil: A Systematic Assessment of Methodological Quality and Transparency |
title_full | Non-Communicable Disease Clinical Practice Guidelines in Brazil: A Systematic Assessment of Methodological Quality and Transparency |
title_fullStr | Non-Communicable Disease Clinical Practice Guidelines in Brazil: A Systematic Assessment of Methodological Quality and Transparency |
title_full_unstemmed | Non-Communicable Disease Clinical Practice Guidelines in Brazil: A Systematic Assessment of Methodological Quality and Transparency |
title_short | Non-Communicable Disease Clinical Practice Guidelines in Brazil: A Systematic Assessment of Methodological Quality and Transparency |
title_sort | non-communicable disease clinical practice guidelines in brazil: a systematic assessment of methodological quality and transparency |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5112889/ https://www.ncbi.nlm.nih.gov/pubmed/27846245 http://dx.doi.org/10.1371/journal.pone.0166367 |
work_keys_str_mv | AT molinocarolinedegodoirezendecosta noncommunicablediseaseclinicalpracticeguidelinesinbrazilasystematicassessmentofmethodologicalqualityandtransparency AT romanoliebernicolinasilvana noncommunicablediseaseclinicalpracticeguidelinesinbrazilasystematicassessmentofmethodologicalqualityandtransparency AT ribeiroeliane noncommunicablediseaseclinicalpracticeguidelinesinbrazilasystematicassessmentofmethodologicalqualityandtransparency AT demelodanielaoliveira noncommunicablediseaseclinicalpracticeguidelinesinbrazilasystematicassessmentofmethodologicalqualityandtransparency |